In terms of histological type, there were 36 (94.7%) and 2 (5.3%) patients with adenocarcinoma (ADC) and large-cell carcinoma (LCC) subtypes in the PD-1 inhibitor plus chemo group; meanwhile, there were 29 (96.7%) and 1 (3.3%) with ADC and LCC subtypes in the chemo group (P = 1.000). This evidence concerns the gene PDCD1 and adenocarcinoma.